ST Pharm Co.,Ltd. (237690.KQ)
KRW 76200.0
(-1.3%)
KRW 76200.0
(-1.3%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 19.58 Billion KRW | 8.78% |
| 2022 | 18 Billion KRW | 443.46% |
| 2021 | 3.31 Billion KRW | 127.27% |
| 2020 | -12.14 Billion KRW | 34.44% |
| 2019 | -18.52 Billion KRW | -99.92% |
| 2018 | -9.26 Billion KRW | -120.6% |
| 2017 | 44.99 Billion KRW | -26.75% |
| 2016 | 61.42 Billion KRW | 143.86% |
| 2015 | 25.18 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 6.23 Billion KRW | -40.8% |
| 2024 Q2 | 1.01 Billion KRW | -83.79% |
| 2024 Q3 | 9.57 Billion KRW | 847.2% |
| 2023 Q2 | 1.33 Billion KRW | -64.85% |
| 2023 Q3 | 3.93 Billion KRW | 195.16% |
| 2023 Q4 | 10.53 Billion KRW | 167.91% |
| 2023 FY | 19.58 Billion KRW | 8.78% |
| 2023 Q1 | 3.78 Billion KRW | 51.93% |
| 2022 Q1 | 1.9 Billion KRW | 142.13% |
| 2022 Q4 | 2.49 Billion KRW | -75.55% |
| 2022 FY | 18 Billion KRW | 443.46% |
| 2022 Q3 | 10.19 Billion KRW | 199.62% |
| 2022 Q2 | 3.4 Billion KRW | 78.47% |
| 2021 Q4 | -4.52 Billion KRW | -160.34% |
| 2021 FY | 3.31 Billion KRW | 127.27% |
| 2021 Q3 | 7.5 Billion KRW | 39.95% |
| 2021 Q2 | 5.35 Billion KRW | 206.72% |
| 2021 Q1 | -5.02 Billion KRW | -25.66% |
| 2020 Q2 | 2.93 Billion KRW | 171.5% |
| 2020 Q3 | -6.98 Billion KRW | -337.85% |
| 2020 Q4 | -3.99 Billion KRW | 42.75% |
| 2020 FY | -12.14 Billion KRW | 34.44% |
| 2020 Q1 | -4.1 Billion KRW | 57.44% |
| 2019 Q4 | -9.64 Billion KRW | -889.43% |
| 2019 Q2 | -2.64 Billion KRW | 49.84% |
| 2019 Q1 | -5.26 Billion KRW | 36.86% |
| 2019 FY | -18.52 Billion KRW | -99.92% |
| 2019 Q3 | -974.68 Million KRW | 63.11% |
| 2018 Q1 | 794.71 Million KRW | -89.74% |
| 2018 Q3 | -6.66 Billion KRW | -234.76% |
| 2018 FY | -9.26 Billion KRW | -120.6% |
| 2018 Q2 | 4.94 Billion KRW | 522.45% |
| 2018 Q4 | -8.34 Billion KRW | -25.16% |
| 2017 Q4 | 7.74 Billion KRW | -1.77% |
| 2017 Q3 | 7.88 Billion KRW | -50.45% |
| 2017 FY | 44.99 Billion KRW | -26.75% |
| 2017 Q2 | 15.91 Billion KRW | 18.38% |
| 2017 Q1 | 13.44 Billion KRW | 14.52% |
| 2016 Q4 | 11.74 Billion KRW | -27.92% |
| 2016 Q2 | 23.72 Billion KRW | 145.2% |
| 2016 FY | 61.42 Billion KRW | 143.86% |
| 2016 Q1 | 9.67 Billion KRW | 6.83% |
| 2016 Q3 | 16.28 Billion KRW | -31.34% |
| 2015 Q3 | 12.12 Billion KRW | 268.78% |
| 2015 Q4 | 9.05 Billion KRW | -25.31% |
| 2015 Q2 | 3.28 Billion KRW | 0.0% |
| 2015 FY | 25.18 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | -10.38 Billion KRW | 288.594% |
| Hyundai Bioscience Co., Ltd. | -14.49 Billion KRW | 235.049% |
| ABL Bio Inc. | -2.64 Billion KRW | 839.844% |
| Cellid, Co., Ltd. | -11.61 Billion KRW | 268.637% |